Neuros Medical, based in Arden Hills, Minnesota, is betting on Tovello’s track record in med-tech mergers and acquisitions to accelerate the adoption of its flagship device. The ALTIUS system, which is FDA-approved for treating chronic post-amputation pain, utilizes direct electrical nerve stimulation to block pain signals. CEO David Veino noted that the appointment aims to balance the discipline of durable financial systems with the strategic agility needed for the company's next growth phase.

Before his transition to Neuros, Tovello served as Senior Vice President of Finance & Administration at Endotronix. His career has centered on navigating the complexities of the pharmaceutical and medical device sectors, securing both venture and non-dilutive funding. As the company addresses a market segment impacting nearly two million Americans, Tovello’s mandate includes driving operational excellence to expand patient access to what is currently the only FDA-approved device of its kind for targeted, patient-controlled pain relief.